Latest Medtech News
Xeltis has secured an additional €20.5 million in funding, led by Horizon 3 Healthcare, to advance its aXess™ vascular access implant toward FDA approval and US commercialization.
The financing builds on the €50 million raised in 2025 and will support completion of the ongoing US pivotal trial, FDA submission preparations, European commercial rollout, manufacturing scale-up, and continued development of the company's XABG and XPAD programs.
The funding follows the successful treatment of the first commercial aXess™ patient in Germany and reflects continued investor confidence in Xeltis' regenerative implant technology.
“This fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, but also enables us to advance our aXess™ pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs,” said Eliane Schutte, CEO of Xeltis.
